Literature DB >> 3882524

Duodenal mucosa synthesis of prostaglandins in duodenal ulcer disease.

K Hillier, C L Smith, R Jewell, M J Arthur, G Ross.   

Abstract

Synthesis of prostaglandins (PGE2, PGI2 and PGF2 alpha) and thromboxane A2 was investigated in short term incubates of duodenal mucosa biopsies. Mucosa close to the ulcer site synthesised significantly less PGF2 alpha (p less than 0.001) and PGI2 (p less than 0.002) measured as its stable metabolite 6-oxo-PGF1 alpha than healthy mucosa from non-ulcer patients. In paired biopsies taken from the ulcer site and opposite the ulcer in the same patient PGF2 alpha and PGI2 syntheses were both significantly and similarly depressed when compared with normal mucosa. Synthesis of PGE2 and TxA2 (as its stable metabolite TxB2) was not different in any tissue. There is a defect in the ability of the human duodenal mucosa in duodenal ulcer disease to synthesise PGF2 alpha and PGI2; the defect is not limited to the ulcer site.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3882524      PMCID: PMC1432638          DOI: 10.1136/gut.26.3.237

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  16 in total

1.  Stimulation by intragastrically administered E2 prostaglandins of human gastric mucus output.

Authors:  C Johansson; B Kollberg
Journal:  Eur J Clin Invest       Date:  1979-06       Impact factor: 4.686

2.  Mechanisms underlying gastric mucosal damage induced by indomethacin and bile-salts, and the actions of prostaglandins.

Authors:  B J Whittle
Journal:  Br J Pharmacol       Date:  1977-07       Impact factor: 8.739

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Prostaglandin cytoprotection of gastric mucosa.

Authors:  T K Chaudhury; E D Jacobson
Journal:  Gastroenterology       Date:  1978-01       Impact factor: 22.682

5.  Cytoprotection by prostaglandins.

Authors:  A Robert
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

6.  Effect of 16,16-dimethyl prostaglandin E2 on ethanol-induced damage to canine oxyntic mucosa.

Authors:  B L Tepperman; T A Miller; L R Johnson
Journal:  Gastroenterology       Date:  1978-12       Impact factor: 22.682

Review 7.  Prostaglandins and digestive diseases.

Authors:  A Robert
Journal:  Adv Prostaglandin Thromboxane Res       Date:  1980

Review 8.  Gastric antisecretory and antiulcer properties of PGE2, 15-methyl PGE2, and 16, 16-dimethyl PGE2. Intravenous, oral and intrajejunal administration.

Authors:  A Robert; J R Schultz; J E Nezamis; C Lancaster
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

9.  Protective effect of prostaglandin E2 in the gastrointestinal tract during indomethacin treatment of rheumatic diseases.

Authors:  C Johansson; B Kollberg; R Nordemar; K Samuelson; S Bergström
Journal:  Gastroenterology       Date:  1980-03       Impact factor: 22.682

10.  Concentrations of prostaglandin A-, E- and F-like substances in gastric mucosa of normal subjects and of patients with various gastric diseases.

Authors:  W Schlegel; K Wenk; H C Dollinger; S Raptis
Journal:  Clin Sci Mol Med       Date:  1977-03
View more
  15 in total

1.  Prostaglandin protects against bile salt induced increases in proton permeation of duodenal brush border membrane.

Authors:  D Zhao; B H Hirst
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

Review 2.  The role of prostaglandins in gastric mucosal protection.

Authors:  D E Wilson
Journal:  Trans Am Clin Climatol Assoc       Date:  1996

3.  Indomethacin treatment during initial period of acetic acid-induced rat gastric ulcer healing promotes persistent polymorphonuclear cell-infiltration and increases future ulcer recurrence. Possible mediation of prostaglandins.

Authors:  T Arakawa; T Watanabe; T Fukuda; K Higuchi; O Takaishi; K Yamasaki; K Kobayashi; A Tarnawski
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

4.  Proceedings of the British Pharmacological Society. University of Southampton, 17th-19th July 1985. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

5.  Prostaglandins in peptic ulcer disease. An overview of current status and future directions.

Authors:  S J Sontag
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

6.  Eicosanoid synthesis in duodenal ulcer disease: decrease in leukotriene C4 by colloidal bismuth subcitrate.

Authors:  A Ahmed; P R Salmon; C R Cairns; M Hobsley; J R Hoult
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

7.  Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs.

Authors:  N Hudson; M Balsitis; F Filipowicz; C J Hawkey
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

8.  Kinetics of prostaglandin E2 and thromboxane A2 synthesis and suppression of PHA-stimulated peripheral blood mononuclear leucocytes.

Authors:  W Awara; K Hillier; D Jones
Journal:  Immunology       Date:  1986-12       Impact factor: 7.397

9.  Role of mucosal blood flow in duodenal ulcer formation induced by dulcerozine.

Authors:  Y Tsukamoto; H Goto; S Hase; T Arisawa
Journal:  Gastroenterol Jpn       Date:  1991-08

10.  Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine.

Authors:  T Arakawa; T Watanabe; T Fukuda; K Yamasaki; K Kobayashi
Journal:  Dig Dis Sci       Date:  1995-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.